Feb 14 2014
BioTek Instruments, Inc., proudly announces that their Cytation™ 3 Cell Imaging Multi-Mode Reader is a finalist in the 2014 Edison Awards® competition. The distinguished awards, inspired by Thomas Edison's persistence and inventiveness, recognize innovation, creativity and ingenuity in the global economy. Award winners will be announced April 30, 2014 at the Edison Awards Annual Gala, held in the historic Julia Morgan Ballroom in San Francisco, CA.
Cytation 3 is among those finalists recognized by a distinguished panel of senior business executives and academics for innovation and excellence. Patented Cytation 3 combines automated digital microscopy and conventional multi-mode microplate detection to provide both rich phenotypic and well-based quantitative analyses in a streamlined workflow. This unique, parallel data acquisition platform is ideal for both cell-based and biochemical assays, and its modular architecture allows users to select the modes they need now, and easily upgrade as their needs evolve.
Peter Weith, BioTek Vice President of Marketing, Sales and Service noted, "We're honored that our Cytation 3 is recognized as an innovation by our customers and the prestigious Edison Awards, and we will continue to develop new, innovative solutions for our customers' challenges."
"It's exciting to see companies like BioTek continuing Thomas Edison's legacy of challenging conventional thinking," added Frank Bonafilia, Edison Awards' executive director. "Edison Awards recognizes the game changing products and services, and the teams that brought them to consumers."
Timely transition from pediatric to adult care reduces hospitalizations for sickle cell patients